Boehringer Ingelheim to Develop NASH Candidate Based On Dicerna's GalXC Platform
- Germany-based Boehringer Ingelheim has accepted Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) GalXC RNAi candidate for advancement under the existing agreement between the companies to discover and develop novel therapies for the treatment of chronic liver diseases.
- Dubbed DCR-LIV2, the compound will be investigated for the treatment of nonalcoholic steatohepatitis (NASH).
- Acceptance of DCR-LIV2 as a development candidate triggered an undisclosed preclinical milestone payment to Dicerna, which the Company expects to receive in the second quarter of 2021.
- Under the terms of the existing agreement, Dicerna is eligible to receive up to $170 million in potential additional milestone payments related to DCR-LIV2.
- Dicerna is also eligible to receive tiered mid-single-digit royalties on potential global net sales.
- Price Action: DRNA shares are up 1.96% at $29.70 during the market session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs NASHBiotech News Health Care Contracts General
